Background: The identification of suited early detection tests is one among the multiple requirements to reduce cervical cancer incidence in developing countries.
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Background
Cancer of the uterine cervix is the third most common cancer in women around the world and still the leading cancer in women in Sub Sahara Africa [1] . Of the 450,000 new cases every year, over 80 % occur in resource poor countries [1] . In Kenya, the annual crude incidence rate of cervical cancer is 16.5 per 100,000 women with a leading mortality rate of 13.5 in 100,000 women [1, 2] .
Implementation of nationwide screening for cervical cancer has been successful in reducing the incidence and mortality rates of cervical cancer in many countries [3] . A further reduction in disease incidence is suggested to be reached by prophylactic HPV vaccinations, if they are combined with continued screening [4] . However, screening and vaccination coverage in developing countries is dramatically low. In Kenya, only 3.2 % of the female population aged 18-69 have been screened for cervical cancer [2] .
Cervical cancer is caused by long lasting infections of the cervical squamous cell epithelium with human papillomaviruses (HPV). The infection is usually acquired during adolescence when women become sexually active and infection prevalence my reach over 50 % [5] . While the vast majority of women clear the infection, upon persistent HPV infections premalignant alterations (cervical intraepithelial neoplasia, CIN) may occur after several years, which precede the development of cervical cancer. Cervical cancer is largely preventable by detecting premalignant alterations and treat them by ablation or excisional means [5] .
Currently the primary screening tests for cervical cancer in most countries with implemented screening programs is Pap cytology, where a smear is taken from the cervix, stained with a dye cocktail and assessed under a light microscope for neoplastic alterations. Pap screening requires advanced infrastructures and experience as it is characterized by multiple visits for diagnosis and treatment, because it has a low single-test sensitivity of between 55 to 80 % [6, 7] and generates many equivocal results which need further work-up [8] . Before women are referred to treatment, classically by removal of the affected tissue (conization), the test is repeated, the cervix is assessed visually by colposcopy and diagnostic biopsies are taken. Overall Pap cytology-based screening has frequently proven challenging and unworkable in low-resource settings [9] .
Different programs investigate and assess alternative approaches, particularly the use of visual screening methods, such as visual inspection with acetic acid (VIA), for precancer and cancer detection and the use of cryotherapy as a pre-cancer treatment method. This is optimally achieved in a single visit and can be carried out also by competent non-physicians, including nurses and midwives. Because the diagnostic accuracy of VIA is largely heterogeneous, in some setting only reaching a sensitivity of~40 % [10] and thereby missing women with pre-cancer that would need treatment, still alternative tests suited for rural and limited resource conditions are currently designed and should be scientifically evaluated.
Detecting the viral DNA is a highly sensitive test for cervical cancer early detection, detecting more premalignant alterations than Pap cytology, used in addition to Pap cytology in certain settings and currently introduced as an alternative for primary screening in many industrialized countries [11] . However, considering the high prevalence of HPV infections, particularly in young women, detecting HPV DNA is a poorly specific test for real cellular alterations and therefore requires additional triage tests for the specific identification of women needing further work-up or treatment [12] . Much effort is currently spent in evaluating the clinical performance of new biomarkers, in order to reduce referral rates, unnecessary treatments and finally costs. In developing countries new biomarkers are particularly attractive as potential point-of-care tests. They can be used to specifically identify directly at one visit those women that need treatment and may thereby reduce the lost-tofollow-up rate [13] .
There are different biomarkers that have been identified and suggested to improve diagnosis of cervical cancer and its precancerous lesions. One promising marker is the cyclin dependent kinase inhibitor p16 INK4a , which becomes overexpressed in response to viral oncogene E7 expression [14] . A number of studies have investigated the clinical use of p16
INK4a as a specific biomarker for cells with transforming HPV infections [15] . HPV-transformed cells overexpress p16 INK4a but retain the capacity to proliferate and are thus double-positive for p16 INK4a and the proliferation marker Ki-67, while senescent cells express p16
INK4a but are Ki-67 negative [16] . An immunochemical test which in parallel detects p16
INK4a and the proliferation marker Ki-67 (p16
INK4a
/Ki-67 cytology, CINtec PLUS) is designed for application on cytologic smears taken from the uterine cervix with a brush, spread on a glass slide, stained for expression of the two markers and assessed under a light microscope. The test demonstrated high sensitivity comparable to HPV DNA testing but superior specificity compared to HPV DNA testing in a European screening population [15, 17] .
The objective of the present study was to study overall positivity rates of p16
INK4a /Ki-67 cytology in a screening population of Kenyan women and compare it to VIA/VILI and HPV DNA testing. Additionally the study was designed to evaluate the diagnostic performance of the tests to detect high grade CIN.
Results
Characteristics of the study population and proportion of positive VIA/VILI, HPV and p16
INK4a /Ki-67 results
A total of 498 women met the eligibility criteria. After exclusion of women with incomplete personal information (no age documented), no VIA/VILI and/or invalid laboratory results in either Pap cytology (low cell number), p16
INK4a /Ki-67 cytology (low cell number) and/or HPV DNA (no cell pellet), 477 samples remained for evaluation. Mean age of these 477 study participants was 35.6 years, ranging between 18 and 74 years (standard deviation 9.9 years). A detailed socio-demographic characterization of the study population is given in reference [18] . p16 INK4a /Ki-67 cytology was positive in 8.2 % (39/477) of the women, with highest rate of positivity in women of age 36 to 40 years (12.2 %, 10/82) and no positives in women younger than 21 years (Fig. 1) .
Of the 477 women, 20.9 % (100/477) were tested positive for HR-HPV. Highest HPV prevalence was found with 35.7 % (5/14) among women younger than 21 years (18-20 years) and prevalence decreased with older age groups with the lowest prevalence (8.3 %, 1/12) in those older than 55 years (Fig. 1) .
VIA/VILI was only positive in a total of 3.1 % (15/477) of the women with the highest prevalence in the age group 46 to 50 years (9.8 %, 4/41) and no positives in women younger than 21 or older than 55 years (Fig. 1) INK4a/ Ki-67 results (kappa = 0.437, p < 0.001) with total positive and negative agreement of 85.5 %. The majority of samples positive for p16
INK4a/ Ki-67 were also positive for HPV DNA (35/39), however more than half of HPV DNA positive samples were p16
INK4a/ Ki-67 negative (65/100).
Performance of the tests to detect high grade cervical intraepithelial neoplasia
The histopathology of a biopsy is considered as the gold-standard for the diagnosis of cervical dysplasia. Women were invited to colposcopy and biopsy if at least one of the tests VIA/VILI, Pap cytology, HPV DNA, and/or p16 INK4a /Ki-67 was positive. Women with only negative test results were considered as disease negative. Of the 22 women which appeared for colposcopy, 4 had no visible lesion and were thus not biopsied, 8 had normal histology in the punch biopsies, 2 women had CIN1, 2 had CIN2 and 6 women were diagnosed with CIN3. All biopsies were evaluated independently from H&E evaluation for p16
INK4a expression and all CIN2 and CIN3 lesions showed positive diffuse p16
INK4a expression, while normal and CIN1 cases were p16
INK4a -negative, thus supporting the diagnosis of high-grade dysplasia in 8 women (2 CIN2, 6 CIN3).
The 6 lesions diagnosed as CIN3 and the two lesions diagnosed as CIN2 in a punch biopsy were all not positive (Table 1) .
As an additional estimate of dysplasia detection rates, the proportion of positive VIA/VILI, HPV DNA and p16 (Table 1) .
Discussion
The high incidence of cervical cancer in Kenya and other developing countries is amongst other reasons due to lacking opportunities for early detection followed by treatment of pre-invasive lesions when necessary.
Visual inspection (VIA and VILI) is used in some setting with variable sensitivity and specificity [10] . HPV DNA testing is being evaluated in developing countries as a more objective test with higher sensitivity and limited specificity [19] . The aim of the present study was to evaluate p16
INK4a /Ki-67 dual-stain cytology in a screening population of Kenyan women in comparison to HPV DNA testing and VIA/VILI. p16
INK4a is a marker with a potentially favorable diagnostic profile, i.e. low rate of false-positive test results and high detection rate of disease [17, 20] .
HPV DNA testing yielded the highest rate of overall positive results (20.9 %; 100/477) in our study with highest HPV prevalence in women younger than 21 years. Among women with available colposcopy and biopsy HPV DNA testing detected all women with histologically confirmed high grade lesions (n = 8), but was also positive in 91.7 % (11/12) of women with normal histology. p16
INK4a /Ki-67 cytology yielded a lower overall rate of positive results (8.2 %; 39/477) and most importantly no positives in women younger than 21 years. This indicates that the test does not pick up the many transient and non-transforming HPV infections in this age group that most likely do not need to be treated. Furthermore p16
INK4a /Ki-67 cytology was positive in all 6 women with CIN3 lesions, in one of the two CIN2 lesions and in only 8.3 % (1/12) of women with normal histology in the punch biopsy.
In our study p16 INK4a /Ki-67 cytology staining was performed in an experienced laboratory in Heidelberg, Germany. However, the availability as ready-to-use reagents and little technical equipment which is required might give the opportunity to implement it in an environment with less advanced infrastructure. We used the PreservCyt ThinPrep system for cytology preparations in the study as this allowed to use one cervical swab for all tests. However, p16
INK4a /Ki-67 cytology staining can also be performed on conventional cytology smears. There is no published data on direct comparison of p16
INK4a /Ki-67 cytology using both cytologic methods (liquid-based vs conventional) for the same woman; there was however no significant difference in p16
INK4a /Ki-67 cytology performance between women screened with conventional smears compared to women screened with liquidbased cytology demonstrated in a large European primary screening study [17] .
In the present study we solely evaluated the diagnostic performance of the tests; we however would like to point out that there is an urgent need now to complement diagnostic studies by well-designed cost-effectiveness analyses. Presently p16
INK4a
/Ki67, particularly in combination with the ThinPrep system cannot be regarded as affordable for low-resource settings. On the long run however costeffectiveness will largely depend on incentives of ministries, industry and finally the performance of the used tests. In this regard the present study may add an important data set for upcoming initiatives and cost analyses.
VIA/VILI, which is currently used in some regions in developing countries, detected none of the women with histologically proven CIN2+, thus women would have been missed by the test. VIA/VILI has the advantage that it is cheap, requires no advanced equipment and can be used as a point-of-care test allowing for screening and cryotherapy if necessary on the same day. However its diagnostic performance can be poor, as indicated by our result.
Conclusions
Although the sample size is limited by the low number of women which followed the invitation to colposcopy and biopsy, it is a promising finding that p16
INK4a /Ki-67 testing yielded a similar detection rate of CIN2+ and a substantially lower rate of positive tests in women with negative histology compared to HPV DNA. Moreover, the overall lower test positivity rate particularly in young women of p16
INK4a /Ki-67 compared to HPV DNA testing suggests that only little transient infections are picked up and warrants further evaluation of the test in countries with high HPV prevalence. p16
INK4a /Ki-67 cytology can be performed within 5 hours manually and does not necessarily require technical equipment except a heating bath and a microscope, thus potentially being performed at a health facility within one day under standardized and controlled conditions. Assessing the slides does not require morphological interpretation, positive are considered all slides with one or more cells expressing both markers, p16
INK4a and Ki-67. This can be learned in a brief training session even by people without prior cytologic or pathologic training [21] . For further studies also automated software-based evaluations of the slides are well conceivable [22] .
